https://www.prnewswire.co.uk/news-releases/promising-pre-clinical-data-supporting-bergenbios-pipeline-to-be-published-and-presented-at-upcoming-679608233.html
Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at...
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that promising pre-clinical data demonstrating that selective AXL inhibition counteracts the progression...
https://www.biospace.com/bergenbio-asa-invitation-to-first-quarter-2020-results-webcast-presentation
BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation - BioSpace
May 13, 2020 - BerGenBio ASA, will announce its results for the first quarter 2020 on Tuesday 19 May 2020.
first quarterbergenbioasainvitation
https://www.biospace.com/bgb324-bergenbio-s-selective-first-in-class-axl-inhibitor-featured-in-3-clinical-presentations-at-18th-world-conference-on-lung-cancer-in-yokohama
BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations At...
Oct 16, 2017 - BerGenBio announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in...
https://www.prnewswire.co.uk/news-releases/bergenbio-reports-third-quarter-2022-financial-results-and-provides-business-update-301677958.html
BerGenBio reports third quarter 2022 financial results and provides business update
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
third quarterfinancial resultsbergenbioreports2022
https://www.prnewswire.co.uk/news-releases/bergenbio-third-quarter-results-2024-302303714.html
BerGenBio Third Quarter Results 2024
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
third quarterbergenbioresults2024
https://www.prnewswire.co.uk/news-releases/bergenbio-announces-poster-presentation-at-upcoming-sitc-meeting-301972852.html
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
poster presentationbergenbioannouncesupcomingsitc
https://www.bergenbio.com/
BerGenBio - Developing first-in-class AXL inhibitors for aggressive disease
BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers
first in classbergenbiodevelopingaxlinhibitors
https://www.biospace.com/bergenbio-asa-results-for-the-first-quarter-2019
BerGenBio ASA: Results for the First Quarter 2019 - BioSpace
May 9, 2019 - BerGenBio ASA selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2019.
results forthe firstbergenbioasaquarter
https://www.biospace.com/bergenbio-announces-start-of-phase-i-trial-evaluating-first-in-class-anti-axl-antibody-bgb149
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 -...
Jan 9, 2019 - BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio's second novel clinical candidate targeting AXL...